Bioniq, a company specializing in AI-driven personalized supplements based on blood marker data, has announced the closing of a $15 million series B funding round, which was led by principal investors HV Capital and Unbound.

The company is valued at $75 million, and will use the funds to further expand its global market share. The company will focus on product development, including its global laboratory network integrations, market, operational, and human resources expansion in the U.S. and Middle East. It will implement a corporate platform for medical, wellness, and athletic institutions.

The company’s approach to tailor-made solutions based on individual data and health goals has significantly grown in the past year, especially in the U.S. market which represents 50% of the customer base. The company’s ability to provide consumers with quantifiable before-and-after snapshots of users’ nutrient needs is one of its biggest assets, leading to health and athletic partnerships such as with Lanswerhof and UFC.

Athletes who use Bioniq include Manchester United’s Diogo Dalot, and former NBA All-Star Andrei Kirilenko.

“We’ve entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient,” said Vadim Fedotov, co-founder and CEO of Bioniq. “Everyone’s health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users.”

Bioniq has built out a proprietary biochemical database over the last decade, which it reports to be the largest of its kind, based on blood test data from customers across five continents. Its AI-powered, patent-pending algorithm assesses an individual’s height, weight, age, lifestyle, and health goals to identify micronutrient imbalances and create a tailor-made supplement formula.

Bioniq PRO offers the greatest level of personalization and incorporates blood biomarker data into its algorithm, allowing users to either upload existing bloodwork into the system to gain recommendations or book a Bioniq blood test through a partner lab. Tests assess nutrient status, identify imbalances, and address them, with one-on-one nutrition consultations also available to discuss next steps with a dietitian.

Bioniq GO uses the company’s same database and offers a more accessible option based on a questionnaire that prompts the AI algorithm to recommend users with a unique supplement blend based on their responses and previous users’ blood biomarker data.

All of Bioniq’s supplements are “Swiss-made, pharmaceutical-grade, and utilize precise micro-dosing to address bio-individual needs and differences,” according to the company. Each formula contains a unique mix of antioxidants, vitamins, minerals, phytonutrients, amino acids, and prebiotic fiber. Instead of traditional pills or capsules, the product is delivered with patented prebiotic guar granules, designed to mimic the way the body digests food in order to improve bioavailability and minimize nutrient competition.

“Bioniq’s exceptional growth is a testament to its innovative approach for high quality personalized health solutions that professional athletes across the world rely on” said David Kuczek, general partner at HV Capital. “With sales from across 60 countries with the majority coming from North America, the most important market for health solutions globally, Bioniq is well-positioned to continue its trajectory of rapid expansion.”

“Bioniq’s innovative approach to nutrition is based on the idea that everyone has different nutritional needs and deficiencies, and that generic multivitamins are not enough to address them. We are impressed by Bioniq’s vision and technology, and we believe that they are disrupting the supplement industry with their personalized and science-based approach. We are excited to support them as they grow and scale their business,” said Shravin Mittal, CEO of Unbound.